Improving adherence in osteoporosis: A new management algorithm for the patient with osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 2, 2011, Pages 257-268

  Baio, Gianluca ^a   Barbagallo, Mario ^b   D'Avola, Giovanni ^c   Di Luccio, Andrea ^d   Di Tanna, Gian Luca ^e   Falaschi, Paolo ^e   Iolascon, Giovanni ^f   Malavolta, Nazzarena ^g   Robbiati, Federico ^h,i   Ulivieri, Fabio Massimo ^a,j  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PALERMO   (Italy)

^c Servizio Reumatologia Osteoporosi Azienda   (Italy)

^d Azienda Unita' Sanitaria Locale   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h Novartis Pharma   (Italy)

ⁱ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

more..

Author keywords

Adherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; DENOSUMAB; IBANDRONIC ACID; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ALGORITHM; BONE DENSITY; CLINICAL FEATURE; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; FRACTURE; HUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; REVIEW; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; CLINICAL PROTOCOLS; COST OF ILLNESS; FEMALE; HUMANS; MEDICATION ADHERENCE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 78651467821     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.537259     Document Type: Review

References (66)

1. Osteoporosis in the European Union in 2008: ten years of progress and ongoing challenges. International Osteoporosis Foundation 2008. Available from: http://www.iofbonehealth.org/download/osteofound/filemanager/publications/pdf/ eu-report-2008.pdf. [Last accessed 9 July 2010]
2. Kanis JA, Burlet N, Cooper C, et al.; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
3. Piscitelli P, Iolascon G, Gimigliano F, et al.; SIOMMMS study group; CERSUM research group. Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int 2007;18:211-19 (Pubitemid 46090225)
4. Adami S, Bertoldo F, Brandi ML, et al.; Societa Italiana dellOsteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro. Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 2009;61:260-84
5. Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk. Osteoporosis evidence review: systematic reviews of clinical effectiveness. National Institute for Clinical Excellence 2008. Available from: http://www.nice. org.uk/nicemedia/pdf/ OsteoporosisEvidenceReviews190908.pdf. [Last accessed 9 July 2010]
6. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles heel of anti-fracture efficacy. Osteoporos Int 2007;18:711-19 (Pubitemid 46684777)
7. Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster arent enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003;88:3482-6.
8. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8
9. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7 (Pubitemid 351160875)
10. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22.
11. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8 (Pubitemid 40824268)
12. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
13. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008;23:1569-75
14. Canadian Institute for Health Information. Available from: secure.cihi. ca/cihiweb/products/ npduis-aib-bisphosphonates2009-e.pdf. [Last accessed 9 July 2010]
15. Seibel MJ. Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 2006;27:123-38
16. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000;11:533-6
17. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008;19:511-17
18. Rossini M, Bianchi G, Di Munno O, et al.; Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21 (Pubitemid 43781506)
19. Zambon A, Baio G, Mazzaglia G, et al. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Pharmacoepidemiol Drug Saf 2008;17:260-9 (Pubitemid 351404037)
20. Rizzuti C, Girani M, Brandi M. Use of administrative database in region Tuscany to set goals for Triad-like intervention to increase osteoporosis treatment rate and adherence rate after hip fracture. American Society for Bone and Mineral Research (ASBMR) 31st Annual Meeting; 11 - 15 September 2009; Denver, Colorado, US
21. The hidden epidemic: finding a cure for unfilled prescriptions and missed doses. The Boston Consulting Group 2003: Available from: http://www.bcg.com/ publications/publications-splash.jsp. [Last accessed 9 July 2010]
22. The adherence gap: why patients dont continue with treatment. International Osteoporosis Foundation 2005. Available from: http://www. iofbonehealth.org. [Last accessed 9 July 2010]
23. Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 2006;1:415-23
24. Actonel 30 mg film coated tablets: summary of product characteristics. Electronic Medicines Company (2009). Available from: http://emc.medicines.org. uk/medicine/3341/SPC/Actonel+30mg+Film+Coated+Tablets/.[Last accessed 9 July 2010]
25. Fosavance 70 mg/2800 IU tablets: summary of product characteristics. European Medicines Agency 2009. Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ Fosavance/emea-combined-h619en.pdf. [Last accessed 9 July 2010]
26. Bonviva 150 mg film-coated tablets: summary of product characteristics. European Medicines Agency 2009. Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ Bonviva/emea-combined-h501en.pdf. [Last accessed 9 July 2010]
27. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-31 (Pubitemid 47019996)
28. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23 (Pubitemid 38368399)
29. Delmas P, Vrijens B, Roux C, et al. Osteoporosis treatment using reinforcement with bone turnover marker data reduces fracture risk: the IMPACT study. J Bone Miner Res 2004;19:S444
30. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871-86
31. Cuddihy MT, Amadio PC, Gabriel SE, et al. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos Int 2004;15:695-700
32. Guilera M, Fuentes M, Grifols M, et al. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 2006;17:664-71
33. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009;20:2127-34
34. The Innovative Care for Chronic Conditions framework (ICCC). World Health Organization. Available from: http://www.who.int/ diabetesactiononline/about/ ICCC/en/. [Last accessed 9 July 2010]
35. Feldstein AC, Nichols GA, Elmer PJ, et al. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am 2003;85-A:2294-302
36. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010;362:2155-65
37. Pursue high-quality DOTS expansion and enhancement. World Health Organization. Available from: http:// www.who.int/tb/dots/en/. [Last accessed 9 July 2010]
38. Volmink J, Garner P. Directly observed therapy for treating tuberculosis [review]. Cochrane Database Syst Rev 2006:CD003343. Update in: Cochrane Database Syst Rev 2007:CD003343
39. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:151-73
40. Lyles KW, Colon-Emeric CS, Magaziner JS, et al.; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
41. Colon-Emeric CS, Eriksen EF, Lyles KV, et al. Timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction in mortality: HORIZON-Recurrent Fracture Trial. American Geriatrics Society Annual Scientific Meeting; 30 April - May 4 2008; Washington DC
42. Calis KA, Pucino F. Zoledronic acid and secondary prevention of fractures. N Engl J Med 2007;357:1861-2 (Pubitemid 350044809)
43. Jansen JP, Bergman GJ, Huels J, Olson M. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 2009;25:1861-8
44. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900
45. Miksad RA, Gonen M, Lynch TJ, Roberts TG Jr. Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. J Clin Oncol 2009;27:2245-52
46. Reclast: US prescribing information. Food and Drug Administration 2009. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 021817s004lbl.pdf. [Last accessed 9 July 2010]
47. Aclasta 5 mg solution for infusion: summary of product characteristics. European Medicines Agency 2009. Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/aclasta/emea-combined-h595en.pdf. [Last accessed 9 July 2010]
48. Boonen S, Vanderschueren D, Venken K, et al. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Inter Med 2008;264:315-32
49. Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905 (Pubitemid 44082279)
50. Lewiecki EM, Babbitt AM, Piziak VK, et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008;30:605-21
51. Kendler DL, McClung MR, Freemantle N, et al.; on behalf of the DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2010. [Epub ahead of print]
52. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60 (Pubitemid 41368578)
53. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61 (Pubitemid 40911458)
54. Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 2009;102:35-42
55. Strom O, Borgstrom F, Kanis JA, Jonsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009;20:23-34
56. Danese MD, Badamgarav E, Bauer DC. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 2009;24:1819-26
57. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med 2007;146:714-25 (Pubitemid 351639999)
58. Ulivieri FM, Baio G, Di Tanna GL, et al. Region lombardia adoption of zoledronic could be cost effective when compared to other bisfosfonate in the treatment of postmenopausal osteoporosis. Clin Case Min Bone Metab 2008;5:409. P 4-65
59. Malavolta N, Baio G, Di Tanna GL, et al. In emilia romagna adoption of zoledronic acid to treat postmenopausal osteoporosis could be cost effective when compared to other bisfosfonates. Clin Case Min Bone Metab 2008;5:410. P 4-66
60. Iolascon G, Baio G, Di Tanna GL, et al. In region campania zoledronic acid is cost effective when compared to both alendronate and risedronate and this choice shows a small uncertainty range. Clin Case Min Bone Metab 2008;5:421. P 4-77
61. DAvola G, Baragallo M, Baio G, et al. In sicilia zoledronic acid is cost-effective when compared to both alendronate and risedronate and this choice shows a small uncertainty range. Clin Case Min Bone Metab 2008;5:422. P 4-78
62. Baio G, Di Tanna GL, Integlia D, Pammolli F. Health economic evaluation of the treatment of osteoporosis in five Italian regions (poster). ISPOR 12th Annual European Congress; 24 - 27 Oct 2009; Paris
63. Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2010. [Epub ahead of print]
64. Decisioni amministrative del Direttore Generale in pubblicazione dal 24.03.2010 al 07.04.2010. Available from: portale.asl3.umbria.it. [Last accessed 26 October 2010]
65. NICE Best Practice Guidelines on Clinical Audit. Available from: http://www.nice.org.uk/media/796/23/BestPracticeClinicalAudit.pdf [Last accessed 02-12-2010]
66. LUso dei farmaci in Italia: rapporto nazionale gennaio - settembre 2009. National Observatory on the Use of Medicines 2009. Available from: http://www.agenziafarmaco.it/allegati/ rapporto-osmed-gen-set2009.pdf. [Last accessed 9 July 2010]